ELMWOOD PARK, New Jersey, March 4, 2026
Glenmark Pharmaceuticals announced that the U.S. Food and Drug Administration has granted final approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, marking a significant milestone in expanding access to affordable respiratory therapies in the United States. The newly approved inhalation product has been confirmed by regulators to be bioequivalent and therapeutically equivalent to the reference drug Flovent® HFA, a widely prescribed inhaled corticosteroid used in the maintenance treatment of asthma. Importantly, the approval includes a Competitive Generic Therapy (CGT) designation, giving Glenmark a 180-day exclusivity period upon commercialization, allowing the company to strengthen its presence in the U.S. respiratory drug market while providing patients with cost-effective treatment options.
FDA Approval Strengthens Glenmark’s Respiratory Portfolio
The regulatory approval represents a major achievement for Glenmark’s inhalation therapy development program and reflects the company’s ongoing strategy to expand its respiratory portfolio in global pharmaceutical markets. Fluticasone Propionate Inhalation Aerosol is an inhaled corticosteroid designed to reduce airway inflammation and help prevent asthma attacks, making it a critical component in long-term asthma management for millions of patients.
According to the approval documentation, the generic inhaler has demonstrated full therapeutic equivalence to the branded reference product, ensuring that physicians and patients can expect the same safety, efficacy, and quality standards as the originator therapy. The approval also identifies Glenmark as the “first approved applicant” under the Competitive Generic Therapy program, a designation intended to accelerate the availability of generics for medicines with limited competition.
Under this regulatory framework, Glenmark will receive 180 days of market exclusivity for the generic product, enabling the company to launch the treatment in the United States beginning in March 2026. The CGT pathway was introduced to promote competition in pharmaceutical markets while improving access to essential medications for patients.
Advertisement
Expanding Access to Affordable Asthma Treatments
Asthma remains one of the most common chronic respiratory conditions globally, affecting millions of patients and placing a significant burden on healthcare systems. Inhaled corticosteroids such as fluticasone propionate are considered first-line therapies for long-term asthma control, helping to reduce airway inflammation, prevent exacerbations, and improve overall respiratory function.
Industry data indicates that the Flovent® HFA inhalation aerosol market in the United States generated approximately $520 million in annual sales during the 12-month period ending January 2026, highlighting the substantial demand for effective and accessible inhaled therapies. With the introduction of Glenmark’s generic alternative, healthcare providers may have more options for prescribing cost-effective treatments without compromising therapeutic quality.
The company noted that the approval demonstrates the technical expertise required to develop complex inhalation products, which involve specialized formulation techniques, device engineering, and rigorous regulatory evaluation to ensure consistent drug delivery and patient safety.
Executives at Glenmark emphasized that the launch supports the company’s broader mission to expand access to high-quality medicines while maintaining a strong pipeline of respiratory, dermatology, and oncology therapies across global markets. The company currently operates 11 manufacturing facilities and six research and development centers worldwide, supporting the production of branded medicines, generics, specialty drugs, and consumer healthcare products.
Competitive Generic Therapy Program Drives Innovation
The Competitive Generic Therapy (CGT) program plays a critical role in encouraging pharmaceutical companies to develop generic medicines for drugs that previously had limited competition. By offering temporary exclusivity incentives, regulators aim to stimulate innovation in the generics sector and ensure that essential treatments remain accessible to patients.
Glenmark’s successful approval demonstrates how the CGT pathway can accelerate the introduction of complex generic inhalation products while maintaining strict regulatory standards for quality and safety. As respiratory diseases continue to represent a major global health challenge, the availability of cost-effective inhaled therapies may significantly improve patient adherence and treatment outcomes.
Experts believe that the approval of Glenmark’s inhalation aerosol could increase competition in the asthma treatment market and reduce healthcare costs, while supporting broader public health initiatives focused on improving respiratory disease management.
With its 180-day exclusivity period and strong respiratory pipeline, Glenmark is positioned to play a growing role in delivering affordable asthma therapies while expanding its global pharmaceutical footprint.
z
Source: Glenmark press release
